Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor...
13 KB (1,248 words) - 01:31, 18 May 2024
cytotoxic agent from the class of calicheamicins. Gemtuzumab ozogamicin Inotuzumab ozogamicin "マイロターグ点滴静注用5mg インタビューフォーム" [Myrotarg 5mg for intravenous drip...
4 KB (96 words) - 14:02, 24 April 2024
ozogamicin was created in a collaboration between Celltech and Wyeth that began in 1991. The same collaboration later produced inotuzumab ozogamicin....
15 KB (1,212 words) - 14:04, 24 April 2024
trastuzumab and a taxane chemotherapy. The European Commission approved Inotuzumab ozogamicin as a monotherapy for the treatment of adults with relapsed or refractory...
40 KB (4,269 words) - 10:29, 26 June 2024
leukemia (AML). A second calicheamicin-linked monoclonal antibody, inotuzumab ozogamicin (marketed as Besponsa), an anti-CD22-directed antibody-drug conjugate...
16 KB (1,506 words) - 18:06, 10 February 2024
Dostarlimab Durvalumab Elotuzumab Enfortumab vedotin Epcoritamab Inotuzumab ozogamicin Ipilimumab Isatuximab Loncastuximab tesirine Mirvetuximab soravtansine...
12 KB (760 words) - 05:52, 10 June 2024
monoclonal antibodies such as rituximab, obinutuzumab, galiximab, inotuzumab ozogamicin, or epratuzumab and immunomodulators such as lenalidomide and interferon...
67 KB (7,967 words) - 19:22, 29 April 2024
CD22 (section Inotuzumab)
PMC 6325303. PMID 30622147. Research Cf (2019-02-09). "FDA approves inotuzumab ozogamicin for relapsed or refractory B-cell precursor ALL". FDA. Poe JC, Fujimoto...
15 KB (1,761 words) - 16:50, 11 April 2024
Class Targeted conditions Year approved (FDA) Year approved (EMA) Inotuzumab ozogamicin (Besponsa) Anti-CD22 monoclonal antibody-drug conjugate Relapsed...
11 KB (842 words) - 13:15, 12 February 2024
Ankylosing spondylitis Psoriatic arthritis Plaque psoriasis 761072 Link inotuzumab ozogamicin Besponsa Wyeth 8/17/17 intravenous humanized, antibody-drug conjugate...
57 KB (4,072 words) - 07:13, 1 July 2024
mouse CD25 (α chain of IL-2 receptor) graft versus host disease Inotuzumab ozogamicin Besponsa mab humanized CD22 Y Acute lymphoblastic leukemia (ALL)...
135 KB (4,054 words) - 22:35, 2 July 2024
Dostarlimab Durvalumab Elotuzumab Enfortumab vedotin Epcoritamab Inotuzumab ozogamicin Ipilimumab Isatuximab Loncastuximab tesirine Mirvetuximab soravtansine...
12 KB (758 words) - 23:46, 14 March 2024
tablets Semprex-D, an antihistamine and decongestant Inotuzumab ozogamicin and gemtuzumab ozogamicin, both through Celltech's collaboration with Wyeth....
9 KB (811 words) - 09:16, 18 May 2024
L01FA01 Rituximab L01FA02 Ofatumumab L01FA03 Obinutuzumab L01FB01 Inotuzumab ozogamicin L01FB02 Moxetumomab pasudotox L01FC01 Daratumumab L01FC02 Isatuximab...
12 KB (877 words) - 15:36, 25 January 2024
Farletuzumab§ Ficlatuzumab§ Flotetuzumab§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab§ Inotuzumab ozogamicin Labetuzumab§ Lifastuzumab vedotin§ Lintuzumab§...
5 KB (368 words) - 22:00, 19 October 2020
Cytarabine/daunorubicin Celator Pharmaceuticals acute myeloid leukemia Inotuzumab ozogamicin Wyeth Pharmaceuticals B-cell precursor acute lymphoblastic leukemia...
34 KB (180 words) - 22:09, 8 April 2024
inocoterone (INN) inogatran (INN) inolimomab (INN) inolitazone (INN) inotuzumab ozogamicin (INN) Inomax (Ikaria) inosine (INN) inositol nicotinate (INN) Inpefa...
9 KB (483 words) - 20:19, 27 May 2024
therapy. Anti-CD22 monoclonal antibodies have been developed, notably inotuzumab ozogamicin, approved by the FDA in 2017 for relapsed and refractory CD22-positive...
96 KB (467 words) - 06:58, 14 October 2022
Farletuzumab§ Ficlatuzumab§ Flotetuzumab§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab§ Inotuzumab ozogamicin Labetuzumab§ Lifastuzumab vedotin§ Lintuzumab§...
4 KB (241 words) - 11:41, 22 April 2022
Farletuzumab§ Ficlatuzumab§ Flotetuzumab§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab§ Inotuzumab ozogamicin Labetuzumab§ Lifastuzumab vedotin§ Lintuzumab§...
3 KB (129 words) - 01:04, 19 July 2023
quantities of this complex material. The recent development of inotuzumab ozogamicin, a calicheamicin-based antibody-drug conjugate for the treatment...
24 KB (2,705 words) - 03:23, 8 July 2023